Atea Pharmaceuticals, Inc. (AVIR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Atea Pharmaceuticals, Inc. (AVIR) closed at USD 4.63 on 2026-10-14, a change of +44.2 % over the past year, with a market capitalization of USD 363.33M.

Atea Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Atea Pharmaceuticals, Inc. key figures

Previous close

USD 4.63 (2026-10-14)

1-year change

+44.2 %

Market cap

USD 363.33M

Enterprise value

USD 144.29M

P/E ratio (trailing)

-2.17

P/E ratio (forward)

-3.06

EPS (trailing)

-2.09

EPS (forward)

-1.48

PEG ratio

n/a

Price to book

1.78

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

26.96

Employees

55

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Atea Pharmaceuticals, Inc. and compare it with other stocks.